Comparison Overview
SEQENS

SEQENS
21, Chemin de la Sauvegarde, Écully, Auvergne-Rhône-Alpes, FR, 69130
Last Update: 02/04/2026
SEQENS is a worldwide leader in pharmaceutical solutions and specialty ingredients. The group generates a revenue of 1 MM€ and operates 16 manufacturing plants and 9 R&D centers in Europe, North America and Asia. 3,300 employees contribute to the success of SEQENS, am...

Hikma Pharmaceuticals
1 New Burlington Place, London, W1S 2HR, GB
Last Update: 03/04/2026
For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospita...
Compliance Ranges Comparison

SEQENS







Hikma Pharmaceuticals






Benchmark & Cyber Underwriting Signals
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for SEQENS in 2026.
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for Hikma Pharmaceuticals in 2026.
Incident History - SEQENS (X = Date, Y = Severity)
SEQENS cyber incidents detection timeline including parent company and subsidiaries.
Incident History - Hikma Pharmaceuticals (X = Date, Y = Severity)
Hikma Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries.
Notable Incidents

SEQENS

Hikma Pharmaceuticals
FAQ
Latest Global CVEs
Pcapng file parser crash in 4.6.0 to 4.6.7 and 4.4.0 to 4.4.18 allows denial of service
X.509IF protocol dissector crash in 4.6.0 to 4.6.7 and 4.4.0 to 4.4.18 allows denial of service
H.245 protocol dissector crash in 4.6.0 to 4.6.7 and 4.4.0 to 4.4.18 allows denial of service
BUSMASTER file parser abnormal exit in 4.6.0 to 4.6.7 and 4.4.0 to 4.4.18 allows denial of service
Kerberos protocol dissector crash in 4.6.0 to 4.6.7 and 4.4.0 to 4.4.18 allows denial of service